Menu
GeneBe

PRPS1

phosphoribosyl pyrophosphate synthetase 1

Basic information

Region (hg38): X:107628427-107651993

Previous symbols: [ "DFN2" ]

Links

ENSG00000147224NCBI:5631OMIM:311850HGNC:9462Uniprot:P60891AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

  • hearing loss, X-linked 1 (Strong), mode of inheritance: XL
  • Charcot-Marie-Tooth disease X-linked recessive 5 (Strong), mode of inheritance: XL
  • Arts syndrome (Strong), mode of inheritance: XL
  • Charcot-Marie-Tooth disease X-linked recessive 5 (Definitive), mode of inheritance: XLR
  • hearing loss, X-linked 1 (Definitive), mode of inheritance: XLR
  • phosphoribosylpyrophosphate synthetase superactivity (Definitive), mode of inheritance: XLR
  • Arts syndrome (Definitive), mode of inheritance: XLR
  • Arts syndrome (Supportive), mode of inheritance: XL
  • X-linked nonsyndromic hearing loss (Supportive), mode of inheritance: XL
  • Charcot-Marie-Tooth disease X-linked recessive 5 (Supportive), mode of inheritance: XL
  • mild phosphoribosylpyrophosphate synthetase superactivity (Supportive), mode of inheritance: XL
  • severe phosphoribosylpyrophosphate synthetase superactivity (Supportive), mode of inheritance: XL
  • X-linked intellectual disability-limb spasticity-retinal dystrophy-diabetes insipidus syndrome (Supportive), mode of inheritance: XL
  • PRPS1 deficiency disorder (Definitive), mode of inheritance: XL
  • Arts syndrome (Definitive), mode of inheritance: XL
  • Charcot-Marie-Tooth disease X-linked recessive 5 (Definitive), mode of inheritance: XL
  • hearing loss, X-linked 1 (Definitive), mode of inheritance: XL
  • phosphoribosylpyrophosphate synthetase superactivity (Definitive), mode of inheritance: XL
  • Arts syndrome (Strong), mode of inheritance: XL
  • phosphoribosylpyrophosphate synthetase superactivity (Strong), mode of inheritance: XL
  • phosphoribosylpyrophosphate synthetase superactivity (Limited), mode of inheritance: XL
  • PRPS1 deficiency disorder (Definitive), mode of inheritance: XL

Clinical Genomic Database

Source: CGD

ConditionInheritanceIntervention CategoriesIntervention/Rationale Manifestation CategoriesReferences
Arts syndrome; Deafness, X-linked 1; Phosphoribosylpyrophosphate synthetase I superactivityXLAllergy/Immunology/Infectious; Audiologic/Otolaryngologic; Biochemical; RenalIn Arts syndrome, treatment with S-adenosylmethionine may be beneficial, and due to infectious risk, prophylaxis and early and aggressive treatment of infections may decrease related morbidity and mortality; Several PRPS1-related conditions can include deafness, which can be congenital/prelingual, and early recognition and treatment of hearing impairment may improve outcomes, including speech and language development; In Phosphoribosylpyrophosphate synthetase I superactivity, medical treatment of uric acid overproduction can be beneficialAllergy/Immunology/Infectious; Audiologic/Otolaryngologic; Biochemical; Hematologic; Neurologic; Renal6069085; 5782823; 171280; 6243137; 3017368; 8498830; 8253776; 7593598; 8882866; 8968763; 10503584; 15240907; 5955956; 17701896; 17701900; 20380929; 20021999; 20301738; 22246954; 24528855; 25182139

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the PRPS1 gene.

  • Charcot-Marie-Tooth Neuropathy X (176 variants)
  • not provided (50 variants)
  • Arts syndrome (35 variants)
  • Phosphoribosylpyrophosphate synthetase superactivity (33 variants)
  • Hearing loss, X-linked 1 (27 variants)
  • not specified (12 variants)
  • Inborn genetic diseases;Nephrolithiasis/nephrocalcinosis (7 variants)
  • Charcot-Marie-Tooth disease X-linked recessive 5 (5 variants)
  • Inborn genetic diseases (5 variants)
  • Nephrolithiasis/nephrocalcinosis;Inborn genetic diseases (3 variants)
  • Retinal dystrophy (3 variants)
  • X-linked nonsyndromic hearing loss (2 variants)
  • Charcot-Marie-Tooth, X-linked (2 variants)
  • History of neurodevelopmental disorder (2 variants)
  • Phosphoribosylpyrophosphate synthetase superactivity;Arts syndrome;Hearing loss, X-linked 1;Charcot-Marie-Tooth disease X-linked recessive 5 (1 variants)
  • Hearing loss, X-linked 1;Arts syndrome;Charcot-Marie-Tooth disease X-linked recessive 5;Phosphoribosylpyrophosphate synthetase superactivity (1 variants)
  • Arts syndrome;Hearing loss, X-linked 1;Phosphoribosylpyrophosphate synthetase superactivity;Charcot-Marie-Tooth disease X-linked recessive 5 (1 variants)
  • Arts syndrome;Hearing loss, X-linked 1;Charcot-Marie-Tooth disease X-linked recessive 5;Phosphoribosylpyrophosphate synthetase superactivity (1 variants)
  • Arts syndrome;Charcot-Marie-Tooth disease X-linked recessive 5;Phosphoribosylpyrophosphate synthetase superactivity;Hearing loss, X-linked 1 (1 variants)
  • Hearing loss, X-linked 1;Charcot-Marie-Tooth disease X-linked recessive 5;Phosphoribosylpyrophosphate synthetase superactivity;Arts syndrome (1 variants)
  • Retinal dystrophy;Hearing loss (1 variants)
  • Hearing loss, X-linked 1;Charcot-Marie-Tooth disease X-linked recessive 5;Arts syndrome;Phosphoribosylpyrophosphate synthetase superactivity (1 variants)
  • Phosphoribosylpyrophosphate synthetase superactivity;Charcot-Marie-Tooth disease X-linked recessive 5;Hearing loss, X-linked 1;Arts syndrome (1 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the PRPS1 gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
1
clinvar
78
clinvar
4
clinvar
83
missense
5
clinvar
14
clinvar
58
clinvar
1
clinvar
78
nonsense
1
clinvar
1
start loss
0
frameshift
2
clinvar
1
clinvar
3
inframe indel
1
clinvar
1
splice donor/acceptor (+/-2bp)
1
clinvar
1
clinvar
2
splice region
11
1
12
non coding
17
clinvar
35
clinvar
14
clinvar
66
Total 9 14 79 114 18

Variants in PRPS1

This is a list of pathogenic ClinVar variants found in the PRPS1 region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
X-107628475-CG-C Phosphoribosylpyrophosphate synthetase superactivity • Arts syndrome • Charcot-Marie-Tooth, X-linked • X-linked nonsyndromic hearing loss Likely benign (Jun 14, 2016)367701
X-107628581-T-TGCA not specified Likely benign (Aug 03, 2016)421764
X-107628640-C-T not specified • Charcot-Marie-Tooth Neuropathy X Benign/Likely benign (May 18, 2023)666743
X-107628649-C-A Uncertain significance (May 18, 2023)2504550
X-107628652-C-T Charcot-Marie-Tooth Neuropathy X Likely benign (Dec 09, 2023)1157448
X-107628653-G-C Likely pathogenic (Nov 01, 2018)807796
X-107628655-C-T Charcot-Marie-Tooth Neuropathy X Likely benign (Sep 06, 2023)2806940
X-107628667-G-A Charcot-Marie-Tooth Neuropathy X Likely benign (Nov 05, 2023)2875332
X-107628671-T-C Charcot-Marie-Tooth Neuropathy X Likely benign (Sep 07, 2020)681063
X-107628674-T-C Charcot-Marie-Tooth disease X-linked recessive 5 Pathogenic (Sep 23, 2016)223101
X-107628675-C-T Retinal dystrophy Likely pathogenic (Jan 01, 2017)446161
X-107628682-A-G Charcot-Marie-Tooth Neuropathy X Likely benign (Oct 17, 2023)3016857
X-107628688-T-C Charcot-Marie-Tooth Neuropathy X • Nephrolithiasis/nephrocalcinosis Likely benign (Jun 28, 2023)543929
X-107628691-C-T Charcot-Marie-Tooth Neuropathy X Likely benign (Jun 15, 2022)2064049
X-107628697-G-A Charcot-Marie-Tooth Neuropathy X Likely benign (Jul 16, 2023)1001412
X-107628702-T-C Likely pathogenic (Jan 01, 2024)2673251
X-107628706-G-A Charcot-Marie-Tooth Neuropathy X Likely benign (Dec 13, 2021)766091
X-107628707-C-T Charcot-Marie-Tooth Neuropathy X Likely benign (Nov 03, 2022)1625183
X-107628715-G-A Charcot-Marie-Tooth Neuropathy X Likely benign (Aug 07, 2023)2733768
X-107628717-T-A Charcot-Marie-Tooth Neuropathy X Uncertain significance (Jun 25, 2022)2010512
X-107628719-GT-G Uncertain significance (Dec 29, 2017)503965
X-107628724-T-C Charcot-Marie-Tooth Neuropathy X Likely benign (Apr 08, 2022)1897234
X-107628727-G-A Charcot-Marie-Tooth Neuropathy X Likely benign (Jun 05, 2021)1563990
X-107628739-C-T Charcot-Marie-Tooth Neuropathy X Likely benign (Dec 13, 2021)2194845
X-107628746-A-G Uncertain significance (May 11, 2021)2435261

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
PRPS1protein_codingprotein_codingENST00000372435 722520
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
0.9150.084100000.00
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense3.73101300.07720.000009982113
Missense in Polyphen034.6610573
Synonymous0.4814145.10.9090.00000335621
Loss of Function2.6107.940.005.01e-7158

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.000.00
Ashkenazi Jewish0.000.00
East Asian0.000.00
Finnish0.000.00
European (Non-Finnish)0.000.00
Middle Eastern0.000.00
South Asian0.000.00
Other0.000.00

dbNSFP

Source: dbNSFP

Function
FUNCTION: Catalyzes the synthesis of phosphoribosylpyrophosphate (PRPP) that is essential for nucleotide synthesis.;
Disease
DISEASE: Note=Phosphoribosyl pyrophosphate synthetase I deficiency is a rare condition caused by mutations in PRPS1 that lead to variable disease phenotypes including optic atrophy, retinitis pigmentosa, ataxia, peripheral neuropathy and hearing loss. {ECO:0000269|PubMed:25491489}.; DISEASE: Phosphoribosylpyrophosphate synthetase superactivity (PRPS1 superactivity) [MIM:300661]: Familial disorder characterized by excessive purine production, gout and uric acid urolithiasis. {ECO:0000269|PubMed:7593598, ECO:0000269|Ref.12}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Charcot-Marie-Tooth disease, X-linked recessive, 5 (CMTX5) [MIM:311070]: A form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot- Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies characterized by severely reduced motor nerve conduction velocities (NCVs) (less than 38m/s) and segmental demyelination and remyelination, and primary peripheral axonal neuropathies characterized by normal or mildly reduced NCVs and chronic axonal degeneration and regeneration on nerve biopsy. {ECO:0000269|PubMed:17701900}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: ARTS syndrome (ARTS) [MIM:301835]: A disorder characterized by mental retardation, early-onset hypotonia, ataxia, delayed motor development, hearing impairment, and optic atrophy. Susceptibility to infections, especially of the upper respiratory tract, can result in early death. {ECO:0000269|PubMed:17701896}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Deafness, X-linked, 1 (DFNX1) [MIM:304500]: A form of deafness characterized by progressive, severe-to-profound sensorineural hearing loss in males. Females manifest mild to moderate hearing loss. {ECO:0000269|PubMed:20021999}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=A mutation in PRPS1 has been found in a patient with a phenotype that bridges that of PRSPS1 superactivity and ARTS syndrome with uric acid overproduction without gout but with recurrent infections, sensorineural hearing loss and motor neuropathy. The intermediate phenotype may be because Leu-142 variant affects both allosteric sites that are involved in inhibition of PRPS1 and the ATP-binding site, which suggests that this substitution can result both in a gain-of-function and loss- of-function of PRPP synthetase. {ECO:0000269|PubMed:22246954}.;
Pathway
Purine metabolism - Homo sapiens (human);Pentose phosphate pathway - Homo sapiens (human);Thiopurine Pathway, Pharmacokinetics/Pharmacodynamics;Nucleotide Metabolism;Pentose phosphate pathway (hexose monophosphate shunt);Metabolism of carbohydrates;PRPP biosynthesis;5-Phosphoribose 1-diphosphate biosynthesis;Metabolism (Consensus)

Recessive Scores

pRec
0.292

Intolerance Scores

loftool
rvis_EVS
0.04
rvis_percentile_EVS
56.25

Haploinsufficiency Scores

pHI
hipred
Y
hipred_score
0.572
ghis
0.616

Essentials

essential_gene_CRISPR
N
essential_gene_CRISPR2
N
essential_gene_gene_trap
N
gene_indispensability_pred
E
gene_indispensability_score
0.947

Mouse Genome Informatics

Gene name
Prps1
Phenotype
mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); vision/eye phenotype;

Zebrafish Information Network

Gene name
prps1a
Affected structure
neuromast hair cell
Phenotype tag
abnormal
Phenotype quality
decreased amount

Gene ontology

Biological process
5-phosphoribose 1-diphosphate biosynthetic process;purine nucleobase metabolic process;purine nucleotide biosynthetic process;pyrimidine nucleotide biosynthetic process;nervous system development;nucleoside metabolic process;ribonucleoside monophosphate biosynthetic process;nucleotide biosynthetic process;phosphorylation;urate biosynthetic process;hypoxanthine biosynthetic process
Cellular component
ribose phosphate diphosphokinase complex;cytoplasm;cytosol
Molecular function
magnesium ion binding;ribose phosphate diphosphokinase activity;protein binding;ATP binding;kinase activity;identical protein binding;protein homodimerization activity